Huahui Health

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
HBV/HDV large envelope protein (PreS1 domain)Monoclonal antibody
Chronic Hepatitis BHepatitis Delta
Chronic Hepatitis Delta
Phase 1
PD-1 / CTLA-4 / VEGF-AMultispecific antibody
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
September 2028 (1)
Libevitug (HH-003)Phase 3Chronic Hepatitis D Infection
Est. primary completion 2028-09-12 · NCT07499544 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

May 2026Licensing dealHH160Huahui Health grants BeOne Medicines a global exclusive option and licence for HH160
BeOne Medicines · Source ↗

Financial reports

No financial reports recorded.